CBIH.US Cannabis Bioscience International Holdings Inc.
- Market cap
- USD 1.74M
- P/E
- -
- P/B
- 0.01x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Feb 2026.
Is CBIH.US undervalued?
Graham numberThe Graham number of Cannabis Bioscience International Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cannabis Bioscience International Holdings Inc. fundamental analysis
No fundamental analysis for Cannabis Bioscience International Holdings Inc. yet.
Cannabis Bioscience International Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cannabis Bioscience International Holdings Inc.
Cannabis Bioscience International Holdings, Inc. engages in the provision of educational systems that focuses on medical cannabis in the United States and Latin America, and internationally. The company offers educational services, such as continuing medical education courses for physicians; continuing legal education courses for attorneys; certification courses for physicians; certification for industry workers; general education seminars; and on-site training, as well as c…
Full company profileCannabis Bioscience International Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Feb 28, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cannabis Bioscience International Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 74.0M | 83.5M | 39.5K | 97.9K | 580K | 762K | 215K | 317K | 249K | 303K | 118K |
| Gross Profit | 17.9M | 26.8M | 39.5K | 97.9K | 580K | 758K | 168K | 223K | 203K | 263K | -40.7K |
| Operating Income | 14.1M | 14.3M | -1.28M | -2.71K | -229K | -115K | -888K | -983K | -486K | -421K | -352K |
| EBITDA | -11.2M | 16.2M | -1.28M | -2.71K | -219K | -111K | -834K | -905K | -497K | -336K | -313K |
| Net Income | -13.4M | 10.5M | -1.28M | -2.71K | -226K | -159K | -885K | -1.03M | -651K | -549K | -405K |
| EPS | -1,657 | 809 | -0.28 | 0.00 | -0.03 | -0.02 | -0.11 | -0.10 | -0.06 | -0.05 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 71.7M | 91.0M | - | - | 128K | 149K | 110K | 43.4K | 57.2K | 31.9K | 1.54K |
| Total Liabilities | 21.6M | 25.9M | - | - | 201K | 450K | 471K | 635K | 1.14M | 1.20M | 1.47M |
| Shareholders' Equity | 48.1M | 62.2M | - | - | -73.0K | -301K | -361K | -592K | -1.08M | -1.16M | -1.47M |
| Cash & Short-term Investments | 1.10M | 148K | - | - | 128K | 41.3K | 32.0K | 8.91K | 755.00 | 13.0K | 90.00 |
| Total Debt | 5.45M | 3.98M | - | - | 197K | 423K | 387K | 390K | 437K | 420K | 406K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.2M | 349K | -6.84K | - | -223K | -508K | -856K | -913K | -479K | -330K | -165K |
| Capital Expenditure | 2.69M | 924K | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 6.63 |
| Free Cash Flow | -12.9M | -575K | -6.84K | - | -223K | -508K | -856K | -913K | -479K | -330K | -165K |
| Ratios | |||||||||||
| ROE | -27.9% | 16.8% | - | - | - | - | - | - | - | - | - |
| ROA | -18.7% | 11.5% | - | - | -177.4% | -107.1% | -805.5% | -2,380.2% | -1,139.5% | -1,721.5% | -26,212.8% |
| Net Profit Margin | -18.2% | 12.5% | -3,250.0% | -2.8% | -39.0% | -20.9% | -411.7% | -325.9% | -261.8% | -181.1% | -342.3% |
| Debt to Equity | 0.11x | 0.06x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cannabis Bioscience International Holdings Inc. dividends
Cannabis Bioscience International Holdings Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Sep 28, 2009.
Who owns Cannabis Bioscience International Holdings Inc.
- Insiders 58.41%
- Institutions 0.00%
- Public & others 41.59%
- Shares outstanding 11.6B
- Free float 5.16B
Cannabis Bioscience International Holdings Inc. company profile
- Company name
- Cannabis Bioscience International Holdings Inc.
- Ticker
- CBIH.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2
- Fiscal year end
- May
- Address
- 6201 Bonhomme Road, Houston, TX, United States, 77036
- Phone
- 214 733 0868
- Website
- chnc-hdh.com
About Cannabis Bioscience International Holdings Inc.
Cannabis Bioscience International Holdings, Inc. engages in the provision of educational systems that focuses on medical cannabis in the United States and Latin America, and internationally. The company offers educational services, such as continuing medical education courses for physicians; continuing legal education courses for attorneys; certification courses for physicians; certification for industry workers; general education seminars; and on-site training, as well as consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University. It is also involved in clinical trials and medical research services through its Alpha Research Institute; and sale of CBD products. The company was founded in 2003 and is headquartered in Houston, Texas.
Cannabis Bioscience International Holdings Inc. management
3- Mr. Dante PicazoCEO, Chief Accounting Officer & Director · born 1956
- Mr. John JonesTreasurer & Director · born 1965
- Dr. Jose A. Torres TorresNational Medical Director, Secretary & Director · born 1959